Exactly. If we get approval in next 2 months I will expect we get quick approval in Europe /Canada which adds to the number, you referenced in your post. Probably 10K-12K GBM patients in all three (3) RAs (UK/EU/Can).
Optune cost isn't covered and it's approved for those 4500 patients. They won't cover DCVax either. They certainly won't approve the expense on top of chemo which would be the label requirement as DCVax hasn't even been tested as a monotherapy. I assume you do realize the P3 was concurrent with chemo, right? Maybe not.
Moot point as it will never be approved. Ashkan is renowned on this board. Nothing more.
75% of that market (nGBM patients) didn't even meet the trial criteria.
Cash flow? I bet you still think there were a ton of compassionate use patients too!
And you say I'm the clueless one. Buy more shares. Cheap today, cheaper tomorrow. For free in the near future. Right after LP sells Advent and your $5K investment disappears.
Market Data 
Markets 
